Dublin, June 04, 2021 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends, 2021" report has been added to ResearchAndMarkets.com's offering.
CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as "living drugs."
T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. These receptors are synthetic and do not exist naturally. Once infused into the patient, these CARs enable the T-cells to recognize and get attached to an antigen (specific protein) on the tumor cell leading to the destruction of the tumor.
Since the approval of the first CAR-T cell therapeutic in 2017, widespread research, an exponential increase in clinical trial activity, proliferative M&A activity, and lucrative IPOs have created a robust CAR-T cell market. This billion-dollar market would not have been possible without the remarkable efficacy of Kymriah, Yescarta, Tecartus, and Breyanzi in treating several types of blood cancers.
CAR-T Cell Therapy Market
In 2012, there were only 12 clinical trials investing CAR-T cell therapy products. Today, that number has risen to over 500. Between 2017 and 2021, four CAR-T products reached the market, and this number is projected to reach double digits within five years. The earliest approvals, Kymriah and Yescarta, have been commercially available since 2017 and 2018, respectively, and have been infused into nearly a half million patients worldwide. In July 2020, the U.S. FDA approved a third CAR-T cell therapy, Kite Pharma's brexucabtagene autoleucel (sold as Tecartus). In February 2021, Breyanzi became the fourth CAR-T approval and the first product with RMAT designationto be licensed by the FDA.
All of the approved CAR-T products and nearly 75% of the ongoing clinical trials take an autologous treatment approach. Autologous (self-derived) CAR-T cells are expensive to produce because they are manufactured on a patient-by-patient basis. At times, autologous production can be hampered by a shortage of CAR-T cells or viral vectors. The cost of autologous CAR-T therapy is further escalated by the need for a complex cold chain during transportation. Another key issue is the "vein-to-vein" time or the time that elapses between apheresis and product delivery.
Thus, CAR-T therapies are most often recommended for the end-stage patients who have exhausted all the other treatment options. These challenges drive up the price, making CAR-T therapy unaffordable for a large percentage of patients.
To support the adoption of CAR-T cell therapies, the industry is taking measures to mitigate these challenges. Several CAR-T players have started using efficient gene-transfer tools to impregnate the T cells with CARs. There are numerous examples of partnerships to develop CRISPR and electroporation technologies to modify the T cells. Some companies are also using "on-off" switches that can turn off CAR-T cells to prevent toxicity.
Unfortunately, the goal of achieving CAR-T success against solid tumors remains elusive thus far, with clinical trials demonstrating a severely limited response.
Trends in CAR-T Cell Therapy
CAR-T cell therapy has taken the biotech industry by storm, creating hope that it could usher in a new era of cancer treatment. However, the success stories have come from targeting CD19, which is now considered an antigen that holds the key to a limited range of blood cancers. Presently, this hematological arena is highly competitive and is being targeted by numerous CAR-T cell therapy competitors.
Scientists, investors and developers invariably agree that the key to longer-term success in this sector depends on solving two major problems: identifying antigens other than CD19 that can be targeted with CAR-T therapy with strong efficacy and going beyond liquid cancers into solid tumor indications. CAR-T cell products targeted against solid tumors will undoubtedly offer a larger market potential.
However, it is not an easy task to identify the antigens found on the cells of solid tumors. There are reasons why CD19 is the most common target. It is seen solely on B cells, whose destruction via CAR-T therapy offers a straightforward route for treating B-cell leukemias and lymphomas. At the same time, loss of the body's B cells is not particularly problematic, because their antibody-producing function can be reinstated by injecting intravenous immunoglobulin (IVIG) to patients.
Driving Forces Impacting the CAR-T Cell Therapy Market
2017 was the first year that the U.S. FDA approved a CAR-T cell therapy, approving Kymriah in August 2017 and Yescarta in October 2017. Novartis produced Kymriah, a CAR-T therapy used to treat leukemia, while Gilead/Kite Pharma produced Yescarta, a CAR-T therapy designed for patients with lymphoma. Approvals for these products spread like wildfire, with the EU, Canada, Australia, Japan, and other nations following suit. In July 2020, the U.S. FDA approved the third CAR-T cell therapy, approving Kite Pharma's brexucabtagene autoleucel, sold as Tecartus. It is the first CAR-T therapeutic to treat relapsed or refractory mantle cell lymphoma (MCL).
By February 2021, the U.S. FDA granted approval of Breyanzi (lisocabtagene maraleucel) to Juno Therapeutics, a Bristol-Myers Squibb company. Breyanzi is approved for the treatment of adults with relapsed or refractory large-B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. The approval of these early CAR-T cell therapies has opened the gates for many other types of cell and gene therapies to claim respect, from regulators, as well as the scientific and medical community at large.
Key Topics Covered:
1. REPORT OVERVIEW
2. CHIMERIC ANTIGEN RECEPTOR-T (CAR-T) CELL THERAPY: A BRIEF OVERVIEW
3. A BRIEF HISTORY OF CAR-T CELL THERAPY
4. MANUFACTURE OF CAR-T CELLS
5. CAR-T TARGET ANTIGENS: A BRIEF OVERVIEW
6. CAR-T PATENT LANDSCAPE
7. GLOBAL CAR-T CLINICAL TRIALS: AN OVERVIEW
8. PUBLISHED SCIENTIFIC PAPERS & NIH GRANTS
9. DEAL-MAKING WITHIN THE CAR-T THERAPY SECTOR
10. MARKETED CAR-T PRODUCTS
11. REIMBURSEMENT FOR CAR-T THERAPIES
12. BLOOD CANCERS: AN OVERVIEW
13. MARKET ANALYSIS
14. COMPANY PROFILES
14.1 Aleta BioTherapeutics
14.1.1 Atela's Pipeline
14.2 Allogene Therapeutics
14.2.1 AlloCAR-T Therapy
14.3 Anixa Biosciences, Inc.
14.4 Atara Biotherapeutics
14.4.1 Technology
14.4.2 Next-Generation CAR-T
14.5 Autolus Therapeutics, plc
14.6 Bellicum Pharmaceuticals, Inc.
14.6.1 GoCAR Technology
14.6.2 Bellicum's Pipeline
14.7 BioNTech
14.7.1 Collaborators
14.7.2 Services
14.7.3 Engineered Cell Therapies
14.7.4 CAR-T Programs
14.7.4.1 BNT211
14.7.4.2 BNT212
14.8 bluebird bio
14.8.1 CAR-T Collaborations
14.8.1.1 Collaboration with Celgene
14.8.1.2 Collaboration with Inhibrx
14.8.1.3 Collaboration with TC BioPharm
14.9 Carina Biotech
14.9.1 New CAR-T Cells
14.9.2 CAR-T Access Technologies
14.9.2.1 Chemokine Receptor Mediation
14.9.2.2 Gel Formulation to Deliver CAR-T Cells
14.10 CARsgen Therapeutics
14.11 Cartesian Therapeutics, Inc.
14.11.1 Cartesian's Approach
14.12 CARTherics
14.12.1 Technology
14.13 Celgene Corporation
14.13.1 Lisocabtagene maraleucel (liso-cel)
14.14 Cellectis
14.14.1 Universal Chimeric Antigen Receptor T-Cells (UCARTs)
14.14.1.1 UCART 123
14.14.1.2 UCART22
14.14.1.3 UCARTCS1
14.14.1.4 UCART19
14.14.1.5 ALLO-501
14.14.1.6 ALLO-715
14.15 Celularity, Inc.
14.15.1 P CAR-T
14.16 Celyad Oncology
14.16.1 TIM Technology
14.16.2 shRNA Technology
14.17 Creative Biolabs
14.17.1 CAR Construction and Production Platform
14.18 CRISPR Therapeutics
14.18.1 CRISPR/Cas9 Immuno-Oncology Cell Therapy
14.19 Cytovia Therapeutics
14.20 DiaCarta, Inc.
14.20.1 Personalized CAR-T Immunotherapy Platform
14.21 Empirica Therapeutics
14.21.1 Technology
14.22 Eureka Therapeutics, Inc.
14.23 EXUMA Biotech Corp.
14.23.1 Logic Gate CAR-T Technology
14.23.2 Same-Day CAR-T Therapy
14.24 Fate Therapeutics, Inc.
14.25 Formula Pharmaceuticals, Inc.
14.25.1 Technology
14.26 Gilead Sciences, Inc.
14.26.1 TECARTUS (Brexucabtagene autoleucel)
14.26.2 Yescarta (Axicabtagene ciloleucel)
14.26.3 Cell Therapy
14.27 Gracell Biotechnologies
14.27.1 Dual CAR
14.27.2 FasTCAR
14.27.3 TrUCAR
14.28 iCell Gene Therapeutics
14.28.1 iCell Platforms
14.28.1.1 CARvac
14.28.1.2 Non Gene Edited Universal CARs
14.28.1.3 C-TPS1
14.28.1.4 T-Cell Targeted CARs
14.28.1.5 Compound CARs
14.29 Janssen Biotech, Inc.
14.29.1 JNJ-4528
14.30 Juno Therapeutics
14.31 JW Therapeutics, Co., Ltd.
14.31.1 Relmacabtagene autoleucel (Relma-cel)
14.32 Kite Pharma, Inc.
14.32.1 Kite's Technologies (CAR-T & TCR)
14.32.2 Kite's Therapies
14.32.2.1 Yescarta (Axicabtagene ciloleucel)
14.32.2.2 Tecartus (Brexucabtagene autoleucel)
14.33 MaxCyte, Inc.
14.33.1 CARMA Cell Therapies
14.33.2 Flow Electroporation Technology
14.34 Minerva Biotechnologies Corporation
14.34.1 HuMNC2-CAR44
14.35 Mustang Bio, Inc.
14.36 Nanjing Legend Biotechnology Co., Ltd.
14.36.1 LCAR-B38M/JNJ-4528
14.37 Noile-Immune Biotech
14.38 Novartis International, AG
14.38.1 Kymriah (Tisagenlecleucel)
14.39 Oxford Biomedica plc
14.40 PeproMene Bio, Inc.
14.40.1 BAFF-R CAR-T Cells
14.41 Poseida Therapeutics, Inc.
14.41.1 PiggyBac DNA Modification System
14.41.2 Autologous & Allogeneic Programs
14.41.2.1 P-BCMA-101
14.41.2.2 P-PSMA-101
14.41.2.3 P-BCMA-ALLO1
14.41.2.4 P-MUC1C-ALLO1
14.41.2.5 P-PSMA-ALLO1
14.42 Precigen, Inc.
14.43 Precision Biosciences
14.44 Prescient Therapeutics
14.44.1 OmniCAR Technology
14.45 ProMab Biotechnologies, Inc.
14.45.1 Custom CAR-T Cell Development
14.46 Protheragen
14.46.1 PR-18-01
14.47 Sorrento Therapeutics, Inc.
14.48 TC Biopharm
14.48.1 Co-Stim CAR-T
14.49 T-CURX
14.49.1 CARAMBA
14.50 Tessa Therapeutics, Pvt. Ltd.
14.50.1 CD30 CAR-T Cells
14.50.2 Allogeneic CD30-CAR EBVSTs
14.51 Tmunity Therapeutics, Inc.
14.52 Wugen
14.53 Xyphos Biosciences, Inc.
14.53.1 Xyphos' Strategy
14.54 Ziopharm Oncology, Inc.
14.54.1 Non-Viral CAR-T Therapy
For more information about this report visit https://www.researchandmarkets.com/r/x5n2up
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
